Browse Conditions Browse Medicines

NICE guidance on the diagnosis, assessment and initial management of hyperparathyroidism

For Hyperparathyroidism

The National Institute for Health and Care Excellence (NICE) have updated their guidance on the diagnosis, assessment and initial management of hyperparathyroidism.

The guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long‑term complications and improving quality of life.

The guideline is aimed at:
  • People with suspected or confirmed primary hyperparathyroidism, their families and carers
  • Healthcare professionals

Hyperparathyroidism: the care you should expect
Hyperparathyroidism is a condition in which 1 or more of the 4 parathyroid glands located in the neck start producing too much parathyroid hormone. This raises the level of calcium in the body and can cause a range of symptoms like feeling unusually thirsty, needing to urinate a lot or becoming constipated.

Hyperparathyroidism can be cured by surgery. If surgery isn’t possible, the symptoms can be relieved by treatment with medicine. But hyperparathyroidism often goes unrecognised – usually because it’s mistaken for other problems or for age-related changes (it is more common in people over 50). Without treatment, hyperparathyroidism can cause long-term complications like kidney stones, bone‑related problems and heart disease.

NICE want this guideline to make a difference to people with hyperparathyroidism by making sure:
  • there is better awareness about the symptoms and healthcare professionals know when to test for it
  • people with hyperparathyroidism are diagnosed without delay
  • doctors have clear advice on when to offer surgery for hyperparathyroidism, and how to use tests to decide the best type of surgery
  • people have follow-up checks as often as needed depending on how their condition is managed

© NICE [2019]

Hyperparathyroidism (primary): diagnosis, assessment and initial management. NICE guideline [NG132] Published date: May 2019
Available from: See Link below. All rights reserved. Subject to Notice of rights
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

The information provided by NICE was accurate at the time this article was issued.

NICE: Hyperparathyroidism (primary): diagnosis, assessment and initial management

Reporting of suspected adverse reactions

Reporting suspected adverse reactions (side effects) after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals or patients are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

Disclaimer: This site is designed to offer information for general educational purposes only. The health information furnished on this site and the interactive responses are not intended to be professional advice and are not intended to replace personal consultation with a qualified physician, pharmacist, or other healthcare professional. We cannot provide individual medical advice. You must always seek the advice of a professional for questions related to a disease, disease symptoms, and appropriate therapeutic treatments.

About condition